Ensuring timely antibody delivery in the face of supply chain challenges - contact us for solutions

Goat Anti-Mouse IgG Fab-HRP

Cat. No.:
Goat Anti-Mouse IgG Fab-HRP antibody for use in ELISA assays.
Size Price (USD) Quantity
1.0 mL $110.00
More Information
Isotype Goat IgG
Specificity Reacts with the Fab region of mouse IgG1, IgG2a, IgG2b, IgG2c, and IgG3
Source Pooled antisera from goat hyperimmunized with mouse IgG
Cross Adsorption Mouse IgG Fc; may react with immunoglobulins from other species and the light chains of other mouse immunoglobulins
Purification Method Affinity chromatography on mouse IgG Fab covalently linked to agarose
Conjugate HRP (Horseradish Peroxidase)
Buffer Formulation 50% Glycerol/50% Phosphate buffered saline, pH 7.4
Clonality Polyclonal
Concentration Lot specific
Volume 1.0 mL
Recommended Storage 2-8°C
Applications Quality tested applications for relevant formats include -

RRID Number AB_2794194

Certificate of Analysis Lookup

Enter the Catalog Number and Lot Number for the Certificate of Analysis you wish to view

Need help with this product?
or call 800.722.2255
  1. 1. Beck Z, Matyas GR, Jalah R, Rao M, Polonis VR, Alving CR. Differential immune responses to HIV-1 envelope protein induced by liposomal adjuvant formulations containing monophosphoryl lipid A with or without QS21. Vaccine. 2015;33:5578-87. (ELISA)
  2. 2. Alving CR, Beck Z, inventors; The Government of the United states of America as Represented by the Secretary of the Army, assignee. Non-toxic adjuvant formulation comprising a monophosphoryl lipid A (MPLA)-containing liposome composition and a saponin. United States patent application publication US 2017/0182152 A1. 2017 Jun 29. (ELISA)
  3. 3. Beck Z, Torres OB, Matyas GR, Lanar DE, Alving CR. Immune response to antigen adsorbed to aluminum hydroxide particles: Effects of co-adsorption of ALF or ALFQ adjuvant to the aluminum-antigen complex. J Control Release. 2018;275:12-19. (ELISA)
  4. 4. Lee J, Park E, Min J, Sung S, Jang Y, Shin JS, et al. Systematic editing of synthetic RIG-I ligands to produce effective antiviral and anti-tumor RNA immunotherapies. Nucleic Acids Res. 2018;46:1635-47. (ELISA)
See All References